Thomas Jefferson University

Jefferson Digital Commons
Department of Medical Oncology Faculty
Papers

Department of Medical Oncology

3-10-2022

Cytokines in the Pathogenesis of Large Granular Lymphocytic
Leukemia
Colleen Isabelle
Amy Boles
Nitin Chakravarti
Pierluigi Porcu
Jonathan Brammer

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Part of the Oncology Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Colleen Isabelle, Amy Boles, Nitin Chakravarti, Pierluigi Porcu, Jonathan Brammer, and Anjali Mishra

REVIEW
published: 10 March 2022
doi: 10.3389/fonc.2022.849917

Cytokines in the Pathogenesis
of Large Granular Lymphocytic
Leukemia
Colleen Isabelle 1, Amy Boles 1, Nitin Chakravarti 1, Pierluigi Porcu 1,
Jonathan Brammer 2 and Anjali Mishra 1,3*
1

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology,
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States, 2 Division of Hematology,
The Ohio State University, Columbus, OH, United States, 3 Department of Cancer Biology, Sidney Kimmel Cancer
Center, Philadelphia, PA, United States

Edited by:
Swami P. Iyer,
University of Texas MD Anderson
Cancer Center, United States
Reviewed by:
Gianpietro Semenzato,
University of Padua, Italy
Renato Zambello,
University of Padua, Italy
*Correspondence:
Anjali Mishra
Anjali.Mishra@jefferson.edu
Specialty section:
This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology
Received: 06 January 2022
Accepted: 08 February 2022
Published: 10 March 2022
Citation:
Isabelle C, Boles A, Chakravarti N,
Porcu P, Brammer J and
Mishra A (2022) Cytokines
in the Pathogenesis of Large
Granular Lymphocytic Leukemia.
Front. Oncol. 12:849917.
doi: 10.3389/fonc.2022.849917

Frontiers in Oncology | www.frontiersin.org

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disorder of older
adults characterized by the clonal expansion of cytotoxic T/natural killer cells due to
constitutive pro-survival signaling. In recent years, it has become clear that cytokines and
their receptors are aberrantly expressed in LGLL cells. The exact initiation process of
LGLL is unknown, although several cytokine-driven mechanisms have emerged. Elevated
levels of several cytokines, including interleukin-15 (IL-15) and platelet-derived growth
factor (PDGF), have been described in LGLL patients. Evidence from humans and animal
models has shown that cytokines may also contribute to the co-occurrence of a wide
range of autoimmune diseases seen in patients with LGLL. The goal of this review is to
provide a comprehensive analysis of the link between cytokines and pro-survival signaling
in LGLL and to discuss the various strategies and research approaches that are being
utilized to study this link. This review will also highlight the importance of cytokine-targeted
therapeutics in the treatment of LGLL.
Keywords: interleukins, growth factors, cytokines, LGLL, therapy

INTRODUCTION
Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disorder of older adults
characterized by the clonal expansion of effector cytotoxic T cells or natural killer (NK) cells. The
WHO classiﬁes LGLL into T-cell LGLL (~85% of all cases) and chronic NK-cell lymphoproliferative
disorder (NK-CLPD also known as NK-LGLL) (~10% of all cases) (1). Although sometimes
included in the LGLL family, aggressive NK-cell leukemia (ANKL) is a distinct neoplasm of NK cells
that is nearly always associated with Epstein–Barr virus (EBV) infection and has a very poor
prognosis (2). While T-LGLL and NK-LGLL are classiﬁed as separate disorders, their pathogenesis
is essentially identical and therefore will be considered together in this review.
The exact cause of LGLL is unknown. To date, studies examining the biology of LGLL have
identiﬁed several altered growth factors signaling pathways in these leukemic cells, which induce
molecular aberrancies believed to play a role in the development of LGLL and in its clinical and
laboratory manifestations. This review aims to provide an overview of the role of cytokines in the
development of LGLL.
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that LGLL isolated from patients constitutively express all three
of the IL-15 receptor components: IL-15Ra, bc, and ɣ c.
The proliferation of LGLL cells constitutively expressing IL-15
receptors is enhanced by the addition of exogenous IL-15 in vitro
and showed enhanced cytotoxic activity (20). LGLL cells have
increased membrane-bound IL-15 on their surface as compared to
healthy controls (21). Typically, IL-15 is presented in trans- to NK
and T cells that express IL-2/15Rbɣ. It is therefore interesting that
Chen et al. (18) demonstrated increased levels of soluble IL-15Ra
(sIL-15Ra) in the serum of patients with LGLL as well as
upregulated levels of IL-15Ra mRNA in patient peripheral
blood mononuclear cells (PBMCs). They speculate that this
increased sIL-15Ra in LGLL patient serum could be a product
of increased enzymatic cleavage from cell surfaces or due to
alternative splicing resulting in the soluble isoform. Chen et al.
(18) also showed increased IFNɣ mRNA in PBMCs from T-LGLL
patients, which is known to induce expression of IL-15Ra
in monocytes. IL-15 signaling contributes to LGLL pathogenesis
through several mechanisms including hypermethylating
DNA, altering microRNA expression, and activating several
oncogenic pathways such as Jak/STAT, Ras, PI3K, and NF-kB
(10). Through these mechanisms, as further detailed in
subsequent sections of this review, IL-15 promotes pro-survival
and anti-apoptosis signaling in LGLL as a key player in the
immunopathogenesis of this disease.

OVERVIEW OF LARGE GRANULAR
LYMPHOCYTIC LEUKEMIA
DEVELOPMENT
The importance of cytokine dysregulation in LGLL pathogenesis
has been well established (3). LGLL represents an expansion of
activated cytotoxic lymphocytes that persist after antigenic
stimulation. LGLL is initiated by an unknown pathogenic
trigger or triggers to activate the initial immune cell reaction
and increase the production of pro-inﬂammatory cytokines by
LGL cells (4–7). This causes polyclonal reactive cell expansion.
However, unlike the normal T-cell LGL expansions in response
to antigen, which are controlled and resolved through T-cell
apoptosis or differentiation into the memory T-cell pool, LGLL
cells begin to clonally proliferate (6, 8). This dysregulated clonal
expansion is currently attributed to alterations of multiple prosurvival and anti-apoptotic signaling pathways, especially
constitutively active cytokine signaling (9). The major cytokine
factors and their interactions with oncogenic signaling pathways
in LGLL will be reviewed here.

ABERRANTLY EXPRESSED CYTOKINES
IN LARGE GRANULAR LYMPHOCYTIC
LEUKEMIA

Platelet-Derived Growth Factors

During disease development, LGLL cells may acquire the ability
to sustain proliferative signaling by producing growth
factors and their cognate receptors themselves, resulting in
chronic autocrine proliferative stimulations (10, 11). LGLL
cells can also respond to soluble growth factors present in the
pro-inﬂammatory microenvironment (12). The cytokines that
have emerged as major players in LGLL pathogenesis are
presented below.

Platelet-derived growth factors (PDGFs) are produced by many
different cell types, such as ﬁbroblasts, endothelial cells, and
macrophages. Overproduction of these factors is a known
contributor to many types of cancer and disease (22, 23). The
PDGFs are dimeric growth factors ranging in size from
approximately 27 to 30 kDa. They activate two related
transmembrane tyrosine kinase receptors, PDGF-a and PDGFb, leading to downstream effects (22, 23). The ﬁve PDGF
isoforms are PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and
PDGF-DD. All ligands except PDGF-DD activate PDGF-a
receptor dimerization in the cell. Similarly, all ligands except
the PDGF-AA can activate the a and b receptors in cells (22).
Network modeling of LGLL survival pathways by Zhang et al.
(3) identiﬁed PDGF as a central contributing driver of LGLL
pathogenesis in addition to IL-15 (3). This network analysis
indicated that after T-cell activation, constitutive IL-15 and
intermittent PDGF signaling were sufﬁcient to reproduce
known dysregulations in T-LGLL. Supporting these ﬁndings,
Zhang et al. ( 3) found patients with T-LGLL had
increased circulating levels of PDGF-BB. With the use of
immunohistochemical staining, PDGF-BB protein was
conﬁrmed to be located on LGLL cells. Yang et al. (11) showed
that LGLL cells have increased levels of PDGF-b receptor mRNA
as compared to healthy donor cells. Treating LGLL cell lines with
exogenous PDGF or serum from LGLL patients led to increased
LGLL cell proliferation, which was abrogated by PI3K inhibitor
(11). The authors also demonstrate that downstream targets of
PDGF signaling, PI3K and Akt/ERK, are constitutively active in
LGLL (11). Pharmacologic disruption of this pathway in an

Interleukin-15
Interleukin-15 (IL-15) is a 15-kDa, four-helix bundle cytokine that
plays a crucial role in the development of innate immunity (13). It
is central to NK cell and NK-T cell development and activation.
IL-15 was discovered in 1994 as a T-cell proliferation factor that
shared the interleukin-2 (IL-2) receptor bc and gC subunits (14).
Signaling occurs through the IL-15Rabg heterotrimeric receptor
complex that includes the shared bc and gC chains, as well as a
private a receptor (15). The IL-15 gene consists of 9 exons
spanning approximately 34 kb on chromosome 4q31 in humans
and chromosome 8 in mice, with 73% conservation between
species (13, 16). Both mice and humans have an alternatively
spliced isoform of IL-15 that also encodes the mature IL-15
protein with potentially different secretion capacity (17). IL-15
has wide tissue distribution and is typically expressed by stromal
cells, epithelial cells, and monocytes. However, it is not typically
expressed by T cells. Expression of IL-15 by LGLL cells is
abnormal and promotes LGLL cell survival (10). The role of
IL-15 in the pathogenesis of LGLL has been well documented
(3, 10, 18–20). IL-15 normally regulates T- and NK-cell activation,
proliferation, and cytotoxicity. Zambello et al. (20) established
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LGLL cell line (NKL) and primary patient samples with antiPDGF-BB antibody led to decreases in downstream targets and
increased LGLL cell apoptosis (3, 11). These ﬁndings establish
PDGF as part of an autocrine loop in LGLL allowing tumor
cell survival.

increase the proliferation of LGL cells via Jak/STAT
signaling (33).

Interleukin-17 and Interleukin-23
Interleukin-17 (IL-17) production deﬁnes helper T cells (TH) and
is a central pro-inﬂammatory driver in the immune response
(34). IL-17 signaling leads to increases in granulocytemacrophage colony-stimulating factor (GM-CSF), IL-6,
monocyte chemoattractant protein-1 (MCP-1), macrophage
inﬂammatory protein (MIP-2), and other inﬂammatory
cytokines (34). Outlined by Zawit et al. (35), there may be
potential for immunotherapeutic targeting of the IL-17/-23
signaling axis as a treatment strategy in LGLL. Interleukin-23
(IL-23) signaling through Jak/STAT receptors in TH17 cells can
drive these cells to produce IL-17 and further perpetuate the
production of pro-inﬂammatory cytokines (36).

Interleukin-2
Interleukin-2 (IL-2) is a 16-kDa four alpha-helix bundle cytokine
in the same family as IL-15 (24). Mainly produced by activated T
cells, IL-2 drives T-cell growth and differentiation via interaction
with its heterotrimeric receptor consisting of three subunits a, b,
and gC (25). IL-2R has been shown to be increased in LGLL cells
(26). Yang et al. (27) investigated the link between antigen
activation, IL-2, and Fas-driven death pathways in T-LGLL.
Normally, IL-2 helps to initially activate T cells but then drives
the cell toward apoptosis via activation-induced cell death
(AICD). While it has been established that despite high FasFasL expression LGLL cells are resistant to Fas-mediated
apoptosis, the connection to IL-2 signaling is not completely
understood (27, 28). LGLL cells treated with exogenous IL-2 in
vitro had restored Fas-signaling, but there was no change in cFLIP, a protein that inhibits the formation of the death-inducing
signaling complex (DISC) machinery, compared with LGLL cells
untreated with IL-2. This suggests intact functioning of this
pathway and, instead, a possible disruption in regulation (27). cFLIP has been found to be overexpressed in LGLL patients,
which may contribute to the cells’ resistance to Fas-induced
apoptosis (27). Additionally, IL-2 signaling can activate NF-kB,
Jak/STAT, and MAPK pathways, all of which can drive cell
proliferation and survival (29).

sIL-2R, Interleukin-6, TNF-alpha, Interleukin-8, and
Interleukin-10
sIL-2R, Interleukin-6, TNF-alpha, Interleukin-8, and
Interleukin-10 were increased in the supernatant of LGLL
primary sample cultures compared to controls (26). These
cytokines can inhibit hematopoiesis, and IL-8 has been shown
to lead to neutrophil extravasation. This may contribute to the
neutropenia that these patients experience in addition to other
autoimmune diseases (37).

RANTES, Interleukin-8, MIP-1 Alpha and Beta,
Interleukin-10, Interleukin-18, IFNɣ, and IL1Ra
RANTES, Interleukin-8, MIP-1 alpha and beta, Interleukin-10,
Interleukin-18, IFNɣ, and IL1Ra all have elevated mRNA
transcripts in the PBMCs of LGL patients (38). The sera of
LGLL patients demonstrated elevated levels of RANTES
(Regulated upon Activation, Normal T-cell Expressed and
presumably Secreted), MIP-1b, and IL-18, all of which can
activate the PI3K pathway (38). Further elucidation of the
mechanisms that trigger the transition from the reactive
lymphoproliferation to the extreme monoclonal process and
subsequent leukemogenesis revealed various phenotypic
differences between the healthy and leukemic T-LGL cells.
These differences include the up-modulation of various genes
(IL-8, IL-18, and IFNɣ) and the presence of chemokines (MCP-1
and IP-10/CXXL10) (39). The overexpression of these
chemokines and receptors (including CXCL2, hepatitis A virus
cellular receptor 1, IL-18, and CCR2) in T-LGL cells are
associated with viral infections. These ﬁndings support the
concept that viral infections can lead to the development of TLGL cells. Interestingly, upregulated cytokines are those typically
produced by CD8+ T cells in response to viral infection, lending
evidence to the idea that a virus may be triggering or
perpetuating insult contributing to LGLL cell pathogenesis.

Interleukin-6
Interleukin-6 (IL-6) is a well-known pro-inﬂammatory, four
alpha-helical, cytokine secreted by many cell types including
monocytes and T cells (30). IL-6 induces Jak/STAT and Ras/Erk
signaling through interactions with a unique IL-6R and
membrane-bound gp130 subunits of its receptor (31). Similar
to IL-15, IL-6R can be both cis- and trans-presented to the gp130
receptor subunits, which dimerize to trigger intracellular
downstream signaling (30). Analyses by Teramo et al. (12)
revealed that the non-leukemic cell population in patients with
LGLL is more prone to producing IL-6 than the healthy
counterpart. It was also shown that the high levels of IL-6 that
were observed in patients with LGLL were associated with the
persistent stimulation of STAT3. Inhibiting this signaling with
anti-IL-6 or anti-IL-6Ra antibodies led to decreased
phosphorylated STAT3 and reduced LGL survival (12).
Recently, Kim et al. (32) investigated IL-6 in the plasma of TLGLL patients (n = 9) by STAT3 mutational status as compared
to healthy donors (n = 8). They demonstrated widely upregulated
cytokine proﬁles in the LGLL patients, speciﬁcally greatly
increased IL-6 and IL-15RA, regardless of STAT3 mutation (32).

Epidermal Growth Factor, IP-10/CXCL10,
Granulocyte Colony-Stimulating Factor

Miscellaneous Others
Interleukin-12

Recent serum analysis of LGLL patients by Olson et al. (40)
found reduced epidermal growth factor (EGF) and increased
levels of interferon gamma-induced protein 10 (IP-10) and

Early studies showed that interleukin-12 (IL-12) can act as a costimulatory cytokine in concert with the activation of CD3 to
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Y640F and D661Y are the most common STAT3 alterations,
accounting for roughly 60% of cases (44). These mutations are
typically found in the Src homology 2 (SH2) dimerization and
activation domains of STAT3 gene (43). The gain-of-function
mutations result in stabilized dimerization, enhanced
transcriptional activity, and eventually increased production of
pro-survival proteins (43). In Y640F, the hydrophobic alteration
to the sequence allows independent homodimerization of the
protein (40). When activated, the pSTAT3 complex can then
translocate to the nucleus and enhance the transcription of
oncogenic driver genes such as c-MYC, BCL-xL, and MCL1 (44).
Jerez et al. (45) linked STAT3 mutation status to patient
outcomes and clinical features showing that patients with
somatic STAT3 mutations were signiﬁcantly more likely to
manifest symptoms at the time of diagnosis (p < 0.001). These
patients also typically required more treatments over the course
of their disease and had a shorter “time-to-treatment-failure”
than those who did not harbor STAT3 mutations (45). The
prevalence of autoimmune conditions, such as rheumatoid
arthritis (RA) and autoimmune hemolytic anemia, was also
higher in the STAT3 mutated cohort. Recently, Barilà et al.
(46) provided the ﬁrst evidence that the presence of a STAT3
mutation can negatively affect the survival rate of patients with
LGLL (46).
To further deﬁne these clinical differences, Olson et al. (40)
investigated variations in red blood cell parameters in LGLL
patients grouped by STAT3 mutation type. They found that
males with D661Y STAT3 mutations had signiﬁcantly higher
mean corpuscular volumes (MCVs) and lower hemoglobin levels
as compared to either the Y604F group or healthy donor controls
(40). This has potential implications for STAT3 mutational status
screening of LGLL patients who may present with macrocytic
anemia (40). STAT5b mutations, N642H and Y665F, have also
been found to be gain-of-function mutations in the SH2 domain
and were initially discovered in a small percentage of clinically
aggressive CD8+ T-LGLL (47). However, STAT5b mutations
have subsequently also been identiﬁed in CD4+ T-LGLL
patients, with incidence ranging from 15.2% to 55% reported
(42, 46, 48). Clinically, these CD4+ T-LGLL patients are most
often asymptomatic, without any impact on survival outcomes
(46, 48). Interestingly, a recent investigation into somatic
mutations of 57 NK-LGLL patients speciﬁcally showed that
few (9%) had STAT3 mutations and no STAT5b mutations
were found (49). However, in patients negative for STAT3
mutations, the authors observed mutations in many other
genes related to cancer pathogenesis, including those related to
Ras/MAPK and PI3K/Akt signaling, as well as TET2, which plays
a role in epigenetic modiﬁcation (49). STAT3 mutations have
also been identiﬁed in ~43% of patients with Felty syndrome (FS;
a rare disease that shares many clinical similarities with LGLL),
as well as signiﬁcant increases in ten cytokines common to both
LGLL and FS (50). IL-15Ra, IL-6, MIP-1a, CXCL10, and CSF-1,
as well as oncostatin-M, TNFRSF9, PD-L1, CDCP1, and HGF,
were those notably upregulated in both FS and LGLL, further
emphasizing the link between cytokine and STAT3 dysregulation
and disease pathogenesis (50). These differences in mutational

granulocyte colony-stimulating factor (G-CSF) in LGLL serum
compared to that of healthy donor controls. The authors also
compared cytokine proﬁles between T-LGLL and NK-LGLL,
which they found to be largely similar between the subtypes.
They state that the reason for lowered EGF in LGLL patients is
unknown but conclude increased IP-10 and G-CSF, which
recruit lymphocytes and stimulate the bone marrow
respectively, both ﬁt with the clinical neutropenic context of
the disease.

CYTOKINE-DRIVEN ONCOGENIC
PATHWAYS IN LARGE GRANULAR
LYMPHOCYTIC LEUKEMIA
The interactions of cytokines and the downstream oncogenic
signaling drivers active in LGLL are summarized below and
in Figure 1.

Jak/STAT
There is abundant evidence for dysregulated STAT signaling in
LGLL. First described in 2001 by Epling-Burnette et al.,
constitutive STAT3 activation is one of the deﬁning features of
the pathogenesis of LGLL (41). Approximately 40% of T-LGLL
patients have gain-of-function STAT3 mutations and STAT5b
variants have also been identiﬁed in LGLL subtypes (42, 43).

FIGURE 1 | Contribution of critical cytokine signaling to large granular
lymphocytic leukemia (LGLL) immunopathogenesis. Interleukin (IL)-15,
platelet-derived growth factor (PDGF), IL-2, and IL-6 are all central players in
the immunopathogenesis of LGLL. Dysregulation of these cytokines leads to
constitutive activation of their downstream signaling pathways such as PI3K,
JAK/STAT, Ras/MAPK, and NF-kB. This leads to increased transcription of
oncogenic driver genes such as c-MYC, cyclin D1, and BCL-xL, ultimately
leading to increased malignant cell proliferation and survival. Figure made with
BioRender.com.
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in LGLL, eventually leading to anti-apoptotic signaling via
disruption of DISC formation. This effect was abrogated using
a PI3K inhibitor, LY294002, which restored apoptosis and
showed a reduction in ERK expression, reinforcing the concept
of crosstalk between these two pathways (58).
Akt can also interfere with the regulation of transcription
factor NF-kB by blocking its inhibition. This leads to increased
NF-kB activity and enhanced transcription of oncogenic genes
(59). Administration of the PI3K inhibitor LY294002 also
resulted in signiﬁcantly decreased NF-kB activity in T-LGLL
cells as well as cell apoptosis, and one of two LGLL patients
treated on a phase I study of the dual PI3K d/g inhibitor duvelisib
had a prolonged partial response (3, 60).

landscape delineated by the immunophenotype of the malignant
cells are interesting to consider and may have future applications
with regard to disease screening or treatment strategy in the age
of precision medicine.
Regardless of mutational status, all LGLL patients have
constitutively upregulated STAT3 activity, in large part due to
pro-inﬂammatory cytokine drivers. As previously discussed, IL15 and IL-6 are both increased in LGLL patients and are known
activators of Jak/STAT signaling. There is evidence for IL-15 as a
central pathogenic driver in LGLL initiation and progression
through Jak/STAT signaling (3, 10). Physiologically, it is
important to note that while short-term exposure to IL-15
increases proliferation, survival, and cytotoxic activities of LGL
cells, long-term chronic activation of STAT by IL-15 has been
shown to be leukemogenic (10). As described in Fehninger et al.
(51), mice that were engineered to overexpress IL-15 develop
spontaneous fatal LGLL. However, it is interesting to note that
STAT3 mutations alone are not sufﬁcient to induce LGLL in a
mouse model, suggesting that cytokine signaling and other
pathway dysregulations are critical for oncogenesis (52).

NF-kB
NF-kB is a transcription factor that regulates the survival of
immune cells and can be activated by IL-15, Ras, and Akt/PI3K.
It can translocate to the nucleus, activating the transcription of
pro-survival and anti-apoptotic genes, such as cyclin D1, c-MYC,
BCL-2, and MCL-1, and can induce the production of IL-2 (41,
61–63). Zhang et al. (3) compared nuclear extracts of T-LGLL
cells to nuclear extracts of healthy donor PBMCs and found that
c-Rel, an NF-kB family protein, is increased and constitutively
active in T-LGLL. When NF-kB was inhibited, the T-LGLL cells
had signiﬁcantly induced apoptosis that was not observed in
normal healthy donor PBMCs (p < 0.009) (3). Interestingly, the
authors also showed that the Mcl-1-driven pathogenic effect of
NF-kB in T-LGLL can occur independently of STAT3 signaling,
adding another facet of possible signal compensation to this
complicated disease picture. Recently, Olson et al. (64) identiﬁed
missense mutations in TNFAIP3, a negative regulator and target
of NF-kB, in 8% of a cohort of 39 LGLL patients (64, 65).
TNFAIP3 expression has been previously shown to be
upregulated in LGLL samples, further emphasizing the
importance of NF-kB signaling in LGLL pathogenesis (65, 66).
Yang et al. (67) established a link between the cytokine TRAIL
(Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand)
and NF-kB in LGLL by demonstrating increased TRAIL
mRNA and protein in LGLL cells as well as increased soluble
TRAIL in sera from LGLL patients compared to healthy controls
(67). TRAIL can bind death receptors to induce apoptosis in
tumor cells as well as activate the NF-kB pathway. The LGLL
cells express the TRAIL receptor DcR2, and activation of this
receptor by TRAIL leads to increases in NF-kB signaling.
Through this mechanism, NF-kB’s pro-survival and antiapoptotic activities are further driven by cytokine signaling
in LGLL.

Ras-Raf-1-MEK1-ERK/MAPK
IL-2, IL-6, IL-15, and PDGF can all activate the Ras-Raf-1MEK1-ERK/MAPK signaling pathway. Ras and ERK have been
found to be constitutively active in NK-LGLL. The aggressive
LGLL cell line, PLT-2, has a G12A KRAS mutation (53, 54).
Mizutani et al. (54) postulated that it is the KRAS mutation that
allows the PLT-2 cell line to grow independently from any
exogenous IL-2 stimulation, unlike MOTN-1, a chronic TLGLL line, which requires IL-2 and IL-15 cytokine stimulation
fo r s u rv i va l . I n h i bi t i n g R a s in LG LL c e l ls w i t h a
farnesyltransferase inhibitor, FTI2153, caused ERK inhibition
and induced apoptosis via Fas signaling and independently of
Fas (53). Inhibition of MEK1 also reduced the survival of NKLGLL cells (53). All of this suggests that dysregulation of this
pathway may have both pro-growth and anti-apoptotic
inﬂuences on LGLL cell pathogenesis. The exact mechanisms
by which MEK/ERK signaling are driving LGLL cell survival are
not yet fully deﬁned. However, it has been established that
activated MAPK is capable of regulating anti-apoptotic
proteins. For example, Bcl-2, BAD, and p-ERK can
phosphorylate proto-oncogenic transcription factors in the
nucleus such as Fos and Jun (53, 55). The Ras cascade also has
the ability to crosstalk with PI3K/Akt signaling, further affecting
downstream signaling in LGLL pathogenesis (56).

PI3K/Akt
Activated by Ras signaling, and PDGF, as well as IL-18,
RANTES, and MIP-1, the PI3K/Akt signaling pathway is a
major driver of pro-survival signaling in LGLL (3, 38).
Compared to healthy donors, T-LGLL cells have increased
PI3K/Akt activity, as indicated by higher levels of p-Akt, which
contributes to downstream resistance to apoptosis (56). p-Akt
can activate mTOR, a major driver of cell growth and
proliferation (57). Schade et al. (58) show that Src family
kinases can lead to constitutive activation of the PI3K pathway
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INTERACTION OF ONCOGENIC DRIVERS
AND CYTOKINE SIGNALING PATHWAYS
The frequent co-existence of dysregulated cytokine signaling and
oncogenic mutations has been described in LGLL. The TNFAIP3
missense mutations in NF-kB signaling observed by Johansson
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et al. (66) were signiﬁcantly associated with STAT3 mutations in
LGLL patient samples, a combination also seen in other
lymphomas (66). Coppe et al. (68) identiﬁed CD40LG as a
mutated receptor in LGLL patient samples. CD40LG is
involved in STAT3 signaling, as well as MAPK-Ras-Erk, and
the IL-15 pathways. Interestingly, CD40LG mutations were also
seen as functionally related to TNFAIP3 in the analysis, meaning
that there is also a potential link to NF-kB signaling dysfunction.
In addition to CD40LG lesions, the authors identiﬁed activating
mutations in FLT3 receptor tyrosine kinase, which has
implications for Ras, Jak/STAT, and PI3K/Akt signaling (68).
It has been established that increased IL-15 can affect the
expression of Bcl-2 family genes. However, Hodge et al. (19)
further elucidated a mechanism by which IL-15 may be driving
anti-apoptotic signaling in LGLL pathogenesis. The authors
demonstrate that IL-15 causes upregulation of HDM2, a p53E3 ligase, which can drive proteasomal degradation of Bid, a
protein that is essential for cell apoptosis (19). Through this
mechanism, IL-15 can reduce Bid in T-LGLL and NK-LGLL
samples. Inhibiting IL-15 or the proteasome degradation
pathway in these samples restored Bid levels and showed
increased cell death (19).
Previous work from Mishra et al. (10) demonstrates how
chronic IL-15 exposure can initiate LGLL through NF-kB
signaling and Myc induction in tumor cells. In normal wildtype mouse LGL cells treated with IL-15, this cytokine induces
Myc expression via the NF-kB pathway. Myc was then shown to
mediate increases in aurora kinases A and B. Elevation of
AURKA, AURKB, and MYC was conﬁrmed in primary LGLL
patient samples, and Myc knockdown in mouse LGL cells
showed reduced AurkA and AurkB. The increased aurora
kinases led to centrosome aberrations and result in
chromosomal aneuploidy, which is a consistent ﬁnding in
patient LGLL cells. This chromosomal instability helps drive
leukemic oncogenesis. Concurrent to aurora kinase upregulation,
the IL-15-driven induction of Myc, NF-kB, and Hdac-1 results in
the reduction of miR-29b when these repressor proteins bind to
its promotor. Indeed, miR-29b levels were demonstrated to be
signiﬁcantly decreased in LGLL patients (p < 0.0009) as well as
healthy donor LGL cells exposed to IL-15 (p < 0.003). Mir-29b, in
turn, typically negatively regulates Dnmt3b, a DNA
methyltransferase, with the expression of DNMT3B found to
be elevated in primary LGLL patient cells. Thus, the increased
Dnmt3b in LGLL results in DNA hypermethylation, leading to
further chromosomal instability as well as possible silencing of
tumor suppressor genes (10). Mishra et al. (10) further
demonstrated increased global DNA methylation in primary
samples from LGLL patients, as well as healthy LGL cells
treated with IL-15 in vitro to support this. Through these
mechanisms, it is clear that IL-15 has a critical role in the
pathogenesis of LGLL.
In addition to miR-29b, another miRNA has recently been
implicated in the pathology of LGLL. Mariotti et al. (69)
identiﬁed reduced expression of miR-146b in CD8+ T-LGLL
due to miR-146b promotor hypermethylation. This observed
repression of miR-146b expression was dependent on STAT3
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activation, likely via the action of DNMT1, and could be
experimentally reversed in CD8+ T-LGLL cells by inhibiting
STAT3 (69). Interestingly, the authors also demonstrate how
miR-146b may contribute to the development of neutropenia
in LGLL via interaction with Fas-ligand signaling. Absolute
levels of neutrophils in LGLL patients correlated with miR146b levels and are inversely correlated with the amount of
soluble Fas-ligand (FasL) (69). The authors posit that miR-146btarget protein HuR is increased in CD8+ T-LGLL, which serves
to stabilize the translation of FasL, ultimately leading to
increased levels of FasL in this disease and a mechanism
for the resultant neutropenia. In this way, cytokine drivers of
STAT3 activation can further alter miRNA levels to drive
LGLL pathogenesis.
The loss of suppressor of cytokine signaling-3 (SOCS3) may
also be contributing to the pathogenic potential of IL-6 signaling
in LGLL. SOCS3 is typically induced by IL-6 via p-STAT3.
However, despite the upregulated levels of IL-6 and STAT3
observed in LGLL, Teramo et al. (12) found a decreased
amount of SOCS3 mRNA and protein in LGLL patient
samples compared to healthy donors. Typically, SOCS3 is
responsible for negatively regulating Jak/STAT signaling. The
authors demonstrated that SOCS3 does not respond
appropriately to p-STAT3/IL-6 messaging in the LGLL cells,
which may further drive dysregulated STAT signaling. However,
after treating the LGLL cells with decitabine, a demethylating
compound, appropriate IL-6-driven increases of SOCS3 mRNA
and protein were observed (12). This treatment also correlated
with decreased p-STAT3, decreased Mcl-1, and increased LGLL
apoptosis. Decitabine’s effective mechanism of action,
demethylation, lends support to the conclusion that epigenetic
changes may be silencing normal SOCS3 responses in LGLL.
However, abnormal methylation changes to the SOCS3
promoter were not seen, leading the authors to conclude that
epigenetic modiﬁcation occurs elsewhere (12). In this way, IL-6
and loss of the SOCS3 regulator work together to further drive
Jak/STAT signaling and LGLL pathogenesis.
Olson et al. (64) recently investigated epigenetic changes in
NK-LGLL patient samples. Methylation of TET2 promoter
sequences as well as hypermethylation of negative regulators of
STAT3, PTPRD, and PTPRN was observed. TET2 typically
contributes to DNA demethylation. This study also identiﬁed
loss-of-function mutations in this gene in 28% of their observed
NK-LGLL patients (n = 58). These patients had signiﬁcantly
increased global methylation compared to healthy controls (64).
Thus, in addition to driving increased STAT activation,
epigenetic modiﬁcation may also be facilitating further
enhanced methylation of the genome in LGLL. Another study
analyzed the TET2 mutational hierarchy in NK-CLPD by
performing whole-exome sequencing of different hematopoietic
cells (70). It revealed that the TET2 alteration was shared by NKLGLL and cells of the myeloid compartments. This study
concluded that the multi-hit model could explain the
emergence of TET2 mutations during the early stages of
hematopoietic progenitors (70). TET2 mutations were also
associated with the CD16low phenotype in NK-LGLL (70).
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hypermethylation prevents repressor protein binding and
results in aberrantly increased IL-15 expression. In LGLL cell
line samples, treatment with 5-azacytidine (a hypomethylating
agent) resulted in decreased IL-15 gene expression and decreased
cell viability, lending evidence to epigenetic changes contributing
to IL-15 overexpression in LGLL (71).
PDGF and PDGFR genetic and epigenetic alterations have
been described previously in other hematologic malignancies but
have yet to be characterized in LGLL (75, 76). Changes to PDGF
receptor proteins may allow for ligand-independent activation
and escape from inhibitory mechanisms or degradation
pathways. Possible changes to this pathway need further
investigation in the setting of LGLL, given the central role of
PDGF signaling in disease pathogenesis (3).
There is clear evidence that overproduction of cytokines can
lead to the development of LGLL and various types of cytopenia
in patients with LGLL. The challenge in treating patients with a
heterogeneous disease like LGLL is to identify patients who may
beneﬁt most from blocking the activity of cytokines. The use of
targeted approaches for the neutralization of oncogenic or
immunosuppressive cytokines could provide new opportunities
to develop effective therapeutic strategies for LGLL patients.

Kim et al. (32) recently demonstrated how cytokine and
epigenetic changes in LGLL can be regulated by STAT3
activity. This study demonstrated that IL-15 mRNA expression
levels are signiﬁcantly higher in STAT3 mutated LGLL.
Additionally, T-LGLL patient samples with STAT3 mutations
had high STAT3 levels and increased pSTAT3 compared to
healthy controls. Additionally, increased DNMT1, DNMT3,
EZH2, and MYC protein were seen in T-LGLL compared to
controls. DNMT1, DNMT3, and EZH2 are methyltransferase
enzymes that can affect epigenetic modiﬁcations. These ﬁndings
were recapitulated in KAI3 NK cells with STAT3Y640F or
STAT3G618R mutations, and increased p65, a subunit of NF-kB,
highlighting the crosstalk potential between these signaling
pathways. Treatment of healthy donor CD8+ T cells with IL-6,
IL-15, and MCP-1 cytokines led to enhanced phosphorylation of
STAT3 and increased DNMT1, DNMT3B, and EZH2 protein.
This further deﬁnes a mechanistic link between cytokine
signaling and regulators of epigenetic modiﬁcation. This study
also observed direct binding of mutated STAT3 to DNMT1 and
EZH2 protein, further deﬁning the mechanism of action of this
pathway. Treating STAT3-mutated LGLL cells with
hypomethylating agent 5-azacytidine led to reduced cell
viability, STAT3 phosphorylation, and DNMT1 (32, 71).
Through these results, the authors deﬁne how cytokine
signaling and STAT3 mutations in LGLL can directly drive
epigenetic changes in this disease, clarifying new targets for
further investigation and potential therapeutic intervention.

CYTOKINE-DRIVEN ANIMAL MODELS
OF LARGE GRANULAR LYMPHOCYTIC
LEUKEMIA
The use of animal models of LGLL has greatly enriched our
understanding of the pathogenesis of LGLL and provided the
opportunity to test novel therapeutics in the disease context.
Fehniger et al. (51) developed a transgenic mouse that
overexpressed IL-15 by removing posttranscriptional
checkpoint inhibitors, allowing for more efﬁcient translation
and secretion. These mice developed fatal lymphocytic
leukemia between 12 and 30 weeks of age with an NK-T
signature of CD3+TCRB+DX5+ markers (51). Phenotypically,
the mice developed alopecia, hepatosplenomegaly, weight loss,
and extreme clonal lymphocyte expansion in blood, spleen, and
bone marrow. The authors described a “blast morphology” of
these lymphocytes, which inﬁltrated many organ systems (77).
This model best recapitulates the aggressive T and NK variants of
LGLL. This chronic upregulation of IL-15 can induce oncogenic
signaling pathways to drive the development of LGLL (10).
Klein et al. (78) described a mouse model that expresses the
human STAT5BN642H mutation, which goes on to develop CD8+
T-cell leukemia (78, 79). This stands in contrast to a study by
Dutta et al. (52), which demonstrated that activating STAT3
mutations in mice was not sufﬁcient to induce LGLL. The
STAT5BN642H lesion is a gain-of-function mutation in the SH2
domain. Similar to the IL-15 transgenic mice, both models have
leukemic immunophenotypes positive for CD122, NKp46, and
DX5, mirroring CD3+NK1.1+ T-LGL cells (77, 78). The authors
also showed that these STAT5BN642H mutation mice could be
successfully treated with ruxolitinib, a JAK inhibitor, further

MECHANISMS OF CYTOKINE
DYSREGULATION IN LARGE GRANULAR
LYMPHOCYTIC LEUKEMIA
While it is established that cytokine signaling is involved in LGLL
initiation and maintenance, how the cytokines involved become
upregulated is not well characterized. The working theory for the
initiation of LGLL involves an antigenic insult that triggers an
inﬂammatory state and immune cell reactivity that gets
inappropriately perpetuated through a variety of signaling and
genetic mechanisms (9). It is likely that to some degree, the
hyperactivation of signaling pathways such as Jak/STAT, Ras-RafMek-Erk, PI3K, and NF-kB further drives cytokine production,
release, and response in a feed-forward loop. However, exact details
have not been thoroughly elucidated. IL-6 signaling, for example,
induces STAT3, which has the ability to promote IL-6 gene
expression in an autocrine feed-forward loop, but this has yet to
be demonstrated conclusively in LGLL (72, 73).
In addition to signaling deﬁciencies, mutations and epigenetic
changes may also contribute to cytokine dysregulation in LGLL.
Previous work has shown some evidence for hypermethylation of
the IL-15 promotor in LGLL patient samples compared to
healthy donor cells (71). Mishra et al. (74) have previously
shown increased IL-15 promoter methylation in cutaneous Tcell lymphoma (CTCL), another T-cell malignancy largely driven
b y I L - 15 p a t h o g e n e s is . I n t h e c a s e o f C T C L , t h e
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BNZ-1 is a peptide that binds the common gamma-chain
receptor CD132 and prevents IL-2, IL-9, and IL-15 signaling
(81). Wang et al. (81) treated LGLL cell lines and primary patient
samples with BNZ-1 and showed that in both cases tumor cell
viability decreased and apoptosis increased. Additionally, BNZ-1
blockage of IL-2 and IL-15 signaling led to reductions in
downstream mediators of these cytokine pathways such as pSTAT, p-Akt, and p-ERK targets (81). In vivo, inhibition of IL-15
using BNZ-1, as part of a phase-I/II clinical trial
(NCT03239393), resulted in apoptosis of LGLL cells in nearly
all patients within 24 h of administration and clinical responses
in 20% of patients, clearly demonstrating the crucial role of this
cytokine to LGLL pathogenesis and potential clinical value of this
therapy (82, 83).
5-Azacytidine is a hypomethylating agent that decreased IL15 expression and reduced cell viability in the MOTN-1 LGLL
cell line (71). This evidence further implicates hypermethylation
as a central driver of IL-15 and LGLL pathogenesis. The oral
formulation of this potential treatment is currently being
investigated in phase I/II clinical trial (NCT05141682) in LGLL
patients (71).
Potential therapeutics that have yet to be tested in humans but
have shown efﬁcacy in vitro are siltuximab and tocilizumab.
Siltuximab and tocilizumab are monoclonal antibodies against IL6 and IL-6R, respectively. Currently approved for the treatment of
RA, they inhibit JAK pathway signaling. Treating LGLL patients’
PBMCs with anti-IL-6 antibodies led to malignant cell apoptosis
(12). The co-occurrence of some LGLL patients with RA or RA-like

emphasizing the central role of dysregulated STAT signaling in
LGLL pathogenesis (78).

THERAPEUTIC BLOCKING OF CYTOKINE
SIGNALING IN LARGE GRANULAR
LYMPHOCYTIC LEUKEMIA TREATMENT
Currently, LGLL is not a curable disease, and the mainstay of
treatment remains general immunosuppressive therapy.
Frontline agents include methotrexate, cyclophosphamide, and
cyclosporine, whose efﬁcacy is typically limited to partial
remissions (60). However, with new insights into LGLL
pathogenesis, researchers have brought novel targets of clinical
interest into pharmaceutical development. Of particular interest
is those targeting cytokine signaling, which are outlined in
Table 1 and summarized in Figure 2.
Cytokine-directed therapeutic agents that have been tested
against LGLL in vivo include Hu-Mikb1, BNZ-1, and 5azacytidine. Hu-Mikb1 is a monoclonal antibody against
CD122, the shared b-chain receptor for IL-2 and IL-15 (80,
88). In a phase I clinical trial of Hu-Mikb1 in LGLL patients,
Waldmann et al. (80) observed that Hu-Mikb1 blocked the trans
presentation of IL-15 to T cells but did not affect cis signaling.
The authors demonstrated the safe use of Hu-Mikb1 but did not
ﬁnd any clinical efﬁcacy in LGLL patients (80).

TABLE 1 | Therapies targeting cytokine signaling in Large Granular Lymphocytic Leukemia.
Therapeutic
agent

Mechanism/ﬁndings

Reference

Agents tested against LGLL in vivo
Anti-CD122 (shared IL-2 and IL-15 receptor b-chain) monoclonal antibody. Blocks trans presentation of IL-15 to T cells. In a phase I
study in LGLL, the drug was safe but showed no clinical efﬁcacy.
BNZ-1
Multi-cytokine inhibitor that prevents IL-2, IL-9, and IL-15 from interacting with the gamma receptor subunit CD132. Wang et al. (81)
demonstrated that treating T-LGLL cell lines and primary patient samples with BNZ-1 led to reduced tumor cell viability, decreased
downstream signaling, and increased apoptosis. Additionally, Brammer et al. (83) showed apoptosis of LGLL cells in patients treated
with BNZ-1 within 24 h of treatment. A phase I/II clinical trial (NCT03239392) showed a 90% decline in T and NK cells by day 15 of
treatment (82).
5-azacytidine Hypomethylating agent: treatment of the LGLL cell line MOTN-1 cells with 5-azacytidine resulted in decreased IL-15 expression;
implicating IL-15 promoter hypermethylation as a key driver of IL-15 induced LGLL. Decreasing IL-15 production by demethylating
the promoter is being explored in a phase I clinical trial (NCT05141682) evaluating an oral 5-azacytidine formulation (CC-486) in patients
with LGLL.
Agents tested against LGLL in vitro
Hu-Mikb1

Siltuximab
Anti-IL-6 and anti-IL-6R, monoclonal antibodies currently approved for treatment of rheumatoid arthritis by inhibiting JAK pathway
and
signaling. In vitro anti-IL-6 antibody treatment of LGLL patients’ PBMCs led to malignant cell apoptosis (12).
tocilizumab
Agents of interest in LGLL
Imatinib
mesylate
(STI-571)
Secukinumab
and
ixekizumab
Risankizumab

(80)
(81–83)

(71)

(12, 84)

A receptor tyrosine kinase inhibitor that can target PDGF receptors.

(85)

Anti-IL-17 monoclonal antibodies that prevent IL-17 receptor binding and downstream JAK/STAT and NFkB signaling. Currently,
FDA-approved for ankylosing spondylitis and psoriatic arthritis treatment.

(86)

Anti-IL-23 humanized monoclonal antibody binds the p19 subunit of IL-23 to block signaling. Currently, FDA-approved for plaque
psoriasis treatment.

(87)

LGLL, large granular lymphocytic leukemia; IL, interleukin; PBMCs, peripheral blood mononuclear cells; CML, chronic myelogenous leukemia; FDA, Food and Drug Administration.
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FIGURE 2 | Cytokine-directed therapies of interest in large granular lymphocytic leukemia (LGLL). Mik-b1, a CD122 monoclonal antibody, prevents the transpresentation of interleukin (IL)-15. BNZ-1 binds the common gamma chain CD132, blocking IL-15 and IL-2 signaling. Siltuximab and tocilizumab block IL-6 signaling.
Imatinib mesylate is a receptor tyrosine kinase inhibitor that prevents platelet-derived growth factor (PDGF) signaling. Secukinumab and ixekizumab block IL-17
signaling. Risankizumab binds the p19 subunit of IL-23 to block signaling. Figure made with BioRender.com.

symptoms may especially make this line of treatment inquiry
worthwhile for further investigation.
Agents of interest in LGLL that have yet to be tested in this
disease but align with known LGLL pathogenic mechanisms are
imatinib mesylate (STI-571), secukinumab and ixekizumab, and
risankizumab. Imatinib mesylate (STI-571) is a receptor tyrosine
kinase inhibitor that can target the PDGF receptor to inhibit
signaling (85). While typically used in chronic myelogenous
leukemia (CML), the known pathogenic role of PDGF signaling
in LGLL warrants further investigation into the usefulness of
targeting this cytokine pathway (3). Secukinumab and ixekizumab
are both monoclonal antibodies that prevent IL-17 receptor binding
and limit downstream JAK/STAT and NFkB signaling (86). Given
the role of IL-17 as a pro-inﬂammatory chemoattractant implicated
in the pathology of various autoimmune conditions (which afﬂict a
subset of LGLL patients), blocking IL-17 signaling is a strategy
worth exploring in the setting of LGLL. Similarly, IL-23 can signal
through Jak/STAT receptors in TH17 cells to drive these cells to
produce IL-17, thereby further perpetuating the inﬂammatory
milieu (36). Risankizumab is a monoclonal antibody against IL-23
that binds the p19 subunit of IL-23 to block signaling (87). The IL17/IL-23 signaling axis constitutes an intriguing target of therapeutic
intervention for LGLL based on its known role in driving
inﬂammation and autoimmune conditions. In summary, there are
several novel cytokine-related treatment strategies worth further
investigation in LGLL.

CONCLUSION
Aberrant cytokine expression and signaling are important
components of LGLL pathogenesis. It is not yet clear how
effective interventions that target inﬂammation will be in
preventing the onset and/or progression of LGLL.
Understanding these cytokine signaling pathways and their
various components will help develop novel therapeutic agents
and treatment strategies. The re-establishment of cytokine
homeostasis in LGLL could beneﬁt patients who suffer from this
disease, especially those refractory to current therapeutic options.
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